Same-day dispatch
Order before 2pm ET — ships from Toronto
COA in every box
Batch-matched third-party certificate
Cold-pack shipped
Temperature-controlled packaging
Purity guarantee
Below spec? Replaced or refunded
PT-141
The Only FDA-Approved Sexual Health Peptide — Now Available for Research
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and cyclic heptapeptide analogue of α-MSH. It is notable for being the only peptide compound that has received FDA approval (as Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, establishing its clinical legitimacy. Research has studied bremelanotide for its central nervous system-mediated effects on sexual arousal pathways via MC3R and MC4R receptor activation in both male and female animal models. The broader sexual wellness market is valued at USD $33.77 billion in 2025.
- Melanocortin receptor agonist — a central rather than vascular mechanism
- Phase 3 clinical program data in HSDD
- 99.0% HPLC purity, endotoxin tested
10mg per vial · Lyophilized Powder · Ships same business day from Toronto
Questions about this batch? Text an agent at (905) 993-4764
99.0%
HPLC purity
Batch TR-PT141-2026-001
MC4R
Primary target
Central melanocortin-4 receptor pathway
1,200+
Phase 3 participants
RECONNECT clinical program
Research benefits
Central Arousal Pathway
Studied for MC3R/MC4R receptor activation effects on sexual response in animal models
FDA-Approved Compound
Bremelanotide is the only peptide approved by the FDA for a sexual health indication (Vyleesi, 2019)
Dual-Gender Research
Investigated for arousal and desire pathway modulation in both male and female animal models
Study findings
Summaries of published research on this compound. Findings are reported for scientific context only and do not constitute claims about this product.
RECONNECT phase 3 program
Bremelanotide produced statistically significant improvements in desire and distress scores versus placebo across two identical phase 3 trials.
Obstetrics & Gynecology · 2019
Central mechanism of action
Bremelanotide acts on central melanocortin receptors rather than the vascular system, distinguishing it from PDE5-inhibitor pathways.
Journal of Sexual Medicine · 2016
Melanocortin system review
MC3R/MC4R signalling is implicated in central regulation of sexual response, energy balance and inflammation.
Pharmacological Reviews · 2018
What researchers report
Aggregated, anonymized observations from laboratories ordering this compound. Anecdotal and non-clinical.
Most frequently ordered for receptor-binding and central-pathway research rather than systemic models.
Researchers regularly note the compound's stability in lyophilized form across long study windows.
Consistently one of our top reorder SKUs in the wellness category.
Technical specifications
| Form | Lyophilized Powder |
| Sequence | Cyclic heptapeptide α-MSH analogue |
| Molecular Weight | 1025.18 g/mol |
| Purity | ≥99% |
| Amount | 10mg per vial |
| Storage | Store at -20°C, protect from light |
| Shelf Life | 24 months (stored at -20°C) |
| COA | COA Available → View Lab Results |
Storage & reconstitution
Store lyophilized vial at -20°C, protected from light.
Reconstitute with bacteriostatic water; swirl gently until fully clear.
Refrigerate at 2–8°C and use within 30 days.
Research background
PT-141 (bremelanotide) is a cyclic heptapeptide derived from melanotan-II research and acts on the central melanocortin receptor system.
Unlike vascular-acting compounds, bremelanotide influences arousal through CNS pathways via MC3R and MC4R activation.
It remains the only peptide to ever receive FDA approval for a sexual health indication, marketed as Vyleesi since 2019.
Third-party verified
ISO 17025 accredited lab — Batch TR-PT141-2026-001
HPLC Purity
99.0%
Molecular Weight
✓ Verified
Endotoxin (LAL)
<1.0 EU/mg
Heavy Metals (ICP-MS)
✓ Pass
PT-141 — frequently asked
What receptor does PT-141 target?
It is a melanocortin receptor agonist acting primarily at MC4R in the central nervous system.
How does it differ from PDE5 inhibitors?
PDE5 inhibitors act on vascular smooth muscle; PT-141 acts centrally on melanocortin signalling pathways.
What clinical data exists?
Two identical phase 3 trials (RECONNECT) reported significant improvements versus placebo on validated endpoints.
How fast does it ship?
Orders placed before 2pm ET ship the same business day from Toronto with tracked Canada-wide delivery, typically arriving in 1–3 business days. Cold-pack packaging is used on every shipment.
What if the purity doesn't match the COA?
Every batch is HPLC and mass-spec verified by an ISO 17025 accredited third-party lab, and the batch-matched COA ships with your order. If an independent test comes back below the stated purity, we replace the order or refund it in full.
Is this legal to purchase in Canada?
Yes — these compounds are sold strictly as in-vitro research chemicals for laboratory use. They are not for human or veterinary use, and it is the purchaser's responsibility to comply with applicable federal and provincial regulations.
Ready to add PT-141 to your research?
≥99% HPLC-verified, endotoxin and heavy metals tested, batch-matched COA included. Ships same business day from Toronto.
Research Use Only Disclaimer
This product is sold exclusively for in-vitro research and laboratory use only. It is NOT intended for human or veterinary use, consumption, injection, or any clinical application. This product has not been evaluated by Health Canada, the FDA, or any other regulatory authority for safety or efficacy in humans or animals. Trinity makes no medical claims regarding this compound. Researchers must comply with all applicable federal, provincial/state, and local laws regarding the purchase, storage, and use of research compounds. By purchasing this product, you confirm you are a qualified researcher or licensed professional acting within the bounds of applicable law.